← FDA DRUG APPROVALS

FDA NDA · NDA018991

LIPOSYN II 20%

Sponsor: HOSPIRA

APPLICATION
NDA018991
TYPE
NDA
ORIGINAL APPROVAL
1984-08-27
LATEST ACTION
2003-04-14
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

LIPOSYN II 20%Discontinued
SAFFLOWER OIL 10%, SOYBEAN OIL 10% (10GM/100ML) · INJECTABLE · INJECTION

Approval history

2003-04-14Manufacturing (CMC) · Supplement 25 · standardLetterAP
2001-02-15Labeling · Supplement 17AP
1997-11-17Manufacturing (CMC) · Supplement 22 · standardAP
1996-08-29Manufacturing (CMC) · Supplement 21 · standardAP
1996-08-27Manufacturing (CMC) · Supplement 19 · standardAP
1994-09-22Manufacturing (CMC) · Supplement 18 · standardAP
1991-01-04Manufacturing (CMC) · Supplement 15 · standardAP
1990-11-02Manufacturing (CMC) · Supplement 16 · standardAP
1989-10-24Manufacturing (CMC) · Supplement 14 · standardAP
1989-07-20Labeling · Supplement 13AP
1988-03-04Manufacturing (CMC) · Supplement 11 · standardAP
1986-06-06Manufacturing (CMC) · Supplement 7 · standardAP
1986-04-02Manufacturing (CMC) · Supplement 5 · standardAP
1986-04-01Labeling · Supplement 8AP
1986-02-22Manufacturing (CMC) · Supplement 9 · standardAP
1985-10-03Labeling · Supplement 2AP
1985-10-03Manufacturing (CMC) · Supplement 1 · standardAP
1985-09-12Manufacturing (CMC) · Supplement 4 · standardAP
1985-01-26Manufacturing (CMC) · Supplement 3 · standardAP
1984-08-27Type 4 - New Combination · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →